An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy

BACKGROUND: For lung adenocarcinoma (LUAD) patients receiving platinum-based adjuvant chemotherapy (ACT), predictive signatures extracted from survival data solely are not directly associated with platinum response. Another limitation of reported signatures, commonly based on risk scores summarised...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Qi, Lishuang, Li, Yang, Qin, Yuan, Shi, Gengen, Li, Tianhao, Wang, Jiasheng, Chen, Libin, Gu, Yunyan, Zhao, Wenyuan, Guo, Zheng
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5155365/
https://ncbi.nlm.nih.gov/pubmed/27855439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.370
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados